Substance P release is enhanced from breast cancer cells by DOX, and NK-1R antagonists enhance cell death and ROS production in MDA-MB231 TNBC cells [108], suggesting that substance P antagonism as an adjunct therapy may protect the heart and augment the anti-tumor activity of DOX. Here, TAC1 is linked to breast carcinoma.